Global
testicular cancer therapeutics market is growing with the increasing prevalence
of testicular cancer. The market is expected to witness moderate growth, since
there are already more than 15 drugs that exist in the market for the treatment
of testicular cancer. Increasing prevalence of cancer and rising demand for the
medications with better efficacy and less side effects can be attributed as an
opportunity for oncology. The regulatory bodies such as USFDA, EMA are
supporting the growth of the global market by providing increased funding,
designations and grants for speeding up the drug development process.
Testicular
cancer is the tumor that develops in the testicles. Testicles are the glands
found in men that produce testosterone hormone and sperms. The cause of
testicular cancer is attributable to enormous growth of testicular cells due to
some abnormalities, resulting in the formation of tumor in testicles, causing
testicular cancer. Cryptorchidism, inguinal hernia, congenital abnormalities,
abnormal testicular development and family history can increase the risk of
testicular cancer. Mumps orchitis are also one of risk factors which is a very
rare complication of mumps, which involves the inflammation of testicles. Pain,
swelling, discomfort, sensation of heaviness and sudden fluid accumulation in
scrotum are the main symptoms of testicular cancer.
Request to Get the
Sample Pages at:
Growing
prevalence of testicular cancer and combination therapies for the treatment are
the major driving forces for the testicular cancer therapeutics market. Also
with no drug in Phase III, there is a need for growth in pipeline for better
treatment options, providing increased opportunities to the players in the
market. Some of the marketed drugs for the treatment of testicular cancer
include Blenoxane (Bleomycin), Cisplatin, Cosmegen (Dactinomycin), Cyfos
(Ifosfamide), Etopophos (Etoposide Phosphate) and Velban (Vinblastine Sulfate).
Some of the drug combination available in the market are BEP, JEB, PEB, VIP and
VeIP.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=testicular-cancer-therapeutics-market
The
treatment is more effective if the chemotherapy regimen involves two or more
drugs rather than using any single drug. Therefore, chemotherapy is expected to
have major share in the global testicular cancer therapeutics market.
Some of the
key players operating in the global
testicular cancer therapeutics market are Ovation Pharmaceuticals,
Inc., ZIOPHARM Oncology Inc., Bristol-Myers Squibb Company, Hospira Inc., Teva
Pharmaceutical Industries Ltd., Fresenius Kabi AG and Teva Parenteral
Medicines, Inc.
